Exhibit 99.1 Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights • On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024 • Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in recurrent high- grade glioma, published in Nature • Catalyst-rich 2024 paves way for transformational year NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. ( ...